



Kite- A Gilead Company, Medical Affairs
Request for Applications for the Cell Therapy External Research Program
Biphasic Application Process: Letters of Intent (LOIs) and Full Proposals

Through Medical Affairs, Kite supports the research efforts of academic institutions, clinical investigators, and research networks to help inform the scientific community about the appropriate use of cell therapy. Kite intends to support investigations focused on:

- Novel combinations
- Side effect/safety management combinations
- Orphan B-cell malignancies (e.g., Hairy cell leukemia, Burkitt lymphoma, PTLD)
- Earlier lines of therapy in high risk lymphoma patients (e.g., high FLIPI/GELF in FL)
- B-cell mediated autoimmune disease
- Novel conditioning regimens
- Real world data
- Translational studies characterizing mechanisms of treatment failure, including relapse, pathogenesis of treatment related toxicities, and approaches to support outpatient treatment

Proposed research efforts will be considered out of scope of this program if focused on:

- Studies already planned by or underway at Kite
- Approved/authorized indications other than novel combinations
- Combinations with: BTK inhibitors, IMiDs, checkpoint inhibitors, and anti-CD20 monoclonal antibodies
- Studies of pipeline cell therapies, or malignancies being studied by Kite with pipeline therapies
- B-cell mediated autoimmune disease with neurologic involvement
- Changes in cell dose
- PCNS lymphoma
- Safety combinations with: siltuximab or anakinra
- Translational research accompanying registrational trials

This Request for Applications, via the External Research Program (ERP) process, will initially evaluate LOIs with objectives to develop and perform clinical studies, preclinical/translational research, HEOR investigations or other relevant research that may inform the appropriate use of cell therapy.

LOIs must contain the following:

- Clear scientific objectives based on a scientifically sound research hypothesis
- Plan to publish and present results in scientific forums and to other organizations
- Plan to complete the research within a reasonable timeframe

Awards shall be for research purposes only; ***requests that include routine medical care will not be considered.***

Key Dates & Program Specifics:LOI Submission

2-page concise overview of proposed project and draft budget, using the attached form

20 December, 2018: LOI submission window opens

31 January 2019: LOI submission window closes

LOIs and questions about the application process should be submitted to ERP@kitepharma.com

Full Proposal Application

A review of the LOIs will result in invitations for selected LOI applicants to submit a full proposal.

The approximate timelines below will be followed for those full proposal applications.

April 2019: Notice of LOI outcome, either approved for full application submission or declined

June 2019: Deadline for receipt of full proposal application

September 2019: Notice of full proposal application outcome, either approved provisionally or declined.

There are no geographic limitations to applications.

Kite reserves the right to approve or decline any application. Applications are reviewed by an internal review committee. Award of support in any one cycle does not imply that subsequent support will be awarded without further application and approval.

About Kite, A Gilead Company

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies.

Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.